NO20080420L - Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet - Google Patents

Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet

Info

Publication number
NO20080420L
NO20080420L NO20080420A NO20080420A NO20080420L NO 20080420 L NO20080420 L NO 20080420L NO 20080420 A NO20080420 A NO 20080420A NO 20080420 A NO20080420 A NO 20080420A NO 20080420 L NO20080420 L NO 20080420L
Authority
NO
Norway
Prior art keywords
prolonged release
dependent solubility
active ingredients
release formulation
active ingredient
Prior art date
Application number
NO20080420A
Other languages
English (en)
Inventor
Gareth Lewis
Frederic Andre
Gerard Alaux
Veronique Serre
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080420(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20080420L publication Critical patent/NO20080420L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives en ny formulering for forlenget frigivning av en aktiv bestanddel med en pH avhengig oppløselighet. Formuleringen ifølge oppflrmelsen omfatter en matriksbærer basert på hydrofll polymer irmeholdende en spesiflkk dose av aktiv bestanddel, og omfatter videre ett eller flere surgjørende midler i form av et syresalt av en organisk syre.
NO20080420A 2005-06-28 2008-01-22 Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet NO20080420L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments
PCT/FR2006/001466 WO2007003746A1 (fr) 2005-06-28 2006-06-26 Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph

Publications (1)

Publication Number Publication Date
NO20080420L true NO20080420L (no) 2008-01-22

Family

ID=35708770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080420A NO20080420L (no) 2005-06-28 2008-01-22 Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet

Country Status (30)

Country Link
US (1) US20080089936A1 (no)
EP (1) EP1904037A1 (no)
JP (1) JP2008546830A (no)
KR (1) KR101387839B1 (no)
CN (1) CN101217943B (no)
AR (1) AR057410A1 (no)
AU (1) AU2006264856B2 (no)
BR (1) BRPI0612990A2 (no)
CA (1) CA2611125A1 (no)
CR (1) CR9567A (no)
DO (1) DOP2006000144A (no)
EA (1) EA013745B1 (no)
EC (1) ECSP078010A (no)
FR (1) FR2887455B1 (no)
GT (1) GT200600275A (no)
HN (1) HN2006023741A (no)
IL (1) IL187901A0 (no)
MA (1) MA29560B1 (no)
MX (1) MX2007016238A (no)
MY (1) MY150069A (no)
NO (1) NO20080420L (no)
NZ (1) NZ564069A (no)
PA (1) PA8682701A1 (no)
PE (1) PE20070098A1 (no)
TN (1) TNSN07438A1 (no)
TW (1) TWI446934B (no)
UA (1) UA91553C2 (no)
UY (1) UY29637A1 (no)
WO (1) WO2007003746A1 (no)
ZA (1) ZA200711035B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
EA201490626A1 (ru) * 2011-09-14 2014-08-29 Поузен Инк. Поэтапное дозирование клопидогрела
IT201700011337A1 (it) * 2017-02-02 2018-08-02 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato per la somministrazione di magnesio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
DE59303759C5 (de) * 1992-01-17 2009-04-09 Alfatec-Pharma Gmbh Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
AU3469100A (en) * 1999-01-05 2000-07-24 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid

Also Published As

Publication number Publication date
TWI446934B (zh) 2014-08-01
UA91553C2 (ru) 2010-08-10
JP2008546830A (ja) 2008-12-25
AU2006264856A1 (en) 2007-01-11
HN2006023741A (es) 2011-05-31
ZA200711035B (en) 2009-09-30
KR20080019023A (ko) 2008-02-29
DOP2006000144A (es) 2007-02-28
FR2887455A1 (fr) 2006-12-29
EA013745B1 (ru) 2010-06-30
TNSN07438A1 (en) 2009-03-17
CA2611125A1 (fr) 2007-01-11
CN101217943A (zh) 2008-07-09
CR9567A (es) 2008-02-20
ECSP078010A (es) 2008-01-23
FR2887455B1 (fr) 2007-08-10
AR057410A1 (es) 2007-12-05
UY29637A1 (es) 2007-01-31
GT200600275A (es) 2007-03-29
WO2007003746A1 (fr) 2007-01-11
CN101217943B (zh) 2012-05-23
MY150069A (en) 2013-11-29
EP1904037A1 (fr) 2008-04-02
TW200727921A (en) 2007-08-01
AU2006264856B2 (en) 2011-09-15
EA200800150A1 (ru) 2008-04-28
HK1122731A1 (en) 2009-05-29
MA29560B1 (fr) 2008-06-02
KR101387839B1 (ko) 2014-04-22
PA8682701A1 (es) 2007-01-17
PE20070098A1 (es) 2007-03-01
IL187901A0 (en) 2008-03-20
BRPI0612990A2 (pt) 2011-04-19
US20080089936A1 (en) 2008-04-17
NZ564069A (en) 2012-04-27
MX2007016238A (es) 2008-03-06

Similar Documents

Publication Publication Date Title
DE50211045D1 (de) Medizinische aerosolformulierungen
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
EP1797881A4 (en) MEDICAL COMPOSITION
WO2007037795A3 (en) Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CY1109272T1 (el) Συνθεση παρατεταμενης απελευθερωσεως περιλαμβανουσα συμπολυμερες γαλακτικου οξεος-γλυκολικου οξεος και μεθοδος παρασκευης της
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NO20071667L (no) Farmasoytisk preparat omfattende levetiracetam og fremgangsmate for fremstilling av preparatet
EA200870379A1 (ru) Фармацевтическая композиция с замедленным высвобождением на основе системы высвобождения, включающей кислоторастворимый полимер и ph-зависимый полимер
NO20010531L (no) Medisinske aerosolformuleringer
AR097045A2 (es) Sistema terapéutico transdérmico
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
CY1108766T1 (el) Συνθεσεις και μεθοδοι για την προληψη ή την μειωση της αντοχης των εντομων στα εντομοκτονα
ATE420639T1 (de) Antimykotische mittel
EP2077111A4 (en) ANTIDEPRESSANT
BR0312814A (pt) Levamisol / avermectinas ou similares em solvente de pirrolidona
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
Fitzsimmons et al. Nitric oxide inhibition of Rickettsia rickettsii
TNSN07438A1 (en) Prolonged release formulation of active principles having a ph-dependent solubility
BRPI0405662A (pt) Emplastros contendo turobuterol
ITRM20040168A1 (it) Composizione a rilascio modificato ph dipendente.
BRPI0407456A (pt) Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso
BRPI0513244A (pt) composto de clatrato, método para controlar a concentração de solução aquosa de ingrediente ativo quìmico agrìcola e formulação quìmica agrìcola
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application